Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Operating Leases (2019 - 2025)

Cue Biopharma (CUE) has disclosed Operating Leases for 7 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 127.92% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 127.92% year-over-year, with the annual reading at $2.3 million for FY2025, 127.92% up from the prior year.
  • Operating Leases hit $2.3 million in Q4 2025 for Cue Biopharma, down from $2.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $6.8 million in Q2 2022 to a low of $176000.0 in Q1 2025.
  • Historically, Operating Leases has averaged $3.0 million across 5 years, with a median of $2.9 million in 2025.
  • Biggest five-year swings in Operating Leases: surged 532.4% in 2023 and later tumbled 93.18% in 2025.
  • Year by year, Operating Leases stood at $5.1 million in 2021, then crashed by 90.24% to $500000.0 in 2022, then soared by 532.4% to $3.2 million in 2023, then plummeted by 68.28% to $1.0 million in 2024, then skyrocketed by 127.92% to $2.3 million in 2025.
  • Business Quant data shows Operating Leases for CUE at $2.3 million in Q4 2025, $2.7 million in Q3 2025, and $3.1 million in Q2 2025.